Modeling Pseudomonas aeruginosa Resistance to Ceftolozane: Dissecting ampC and ampD Mutation Effects

Study Background and Research Question

The increasing prevalence of multidrug-resistant (MDR) Pseudomonas aeruginosa poses a critical challenge in clinical settings, particularly given its capacity to rapidly develop resistance to β-lactam/β-lactamase inhibitor combinations such as ceftolozane-tazobactam. While ceftolozane, a time-dependent oxyimino cephalosporin, retains robust bactericidal activity against P. aeruginosa and other Gram-negative pathogens, clinical resistance is frequently observed following treatment. Notably, resistance often emerges via chromosomal mutations in the ampC gene encoding a cephalosporinase, and its regulatory partner ampD. However, the precise quantitative contribution of these mutations to reduced susceptibility—especially considering adaptive versus acquired resistance—remains poorly defined. The referenced study (Deroche et al., 2023) addresses this knowledge gap by leveraging semi-mechanistic pharmacokinetic/pharmacodynamic (PK/PD) modeling to parse the mechanistic roles of specific ampC and ampD mutations in the development of resistance to ceftolozane-tazobactam.

Key Innovation from the Reference Study

The key innovation of the study lies in its integration of sequential time-kill curve experiments with semi-mechanistic PK/PD modeling to quantitatively distinguish the initial and adaptive resistance effects of identified mutations. By generating isogenic P. aeruginosa mutants carrying clinically observed ampC (G183D) and ampD (H157Y) substitutions—alone and in combination—alongside the use of whole genome sequencing, the researchers provide a nuanced map of how these mutations alter susceptibility profiles not only to ceftolozane-tazobactam but also, in parallel, to imipenem. This dual approach enables precise deconvolution of mutation-driven resistance mechanisms and their time-dependent dynamics.

Methods and Experimental Design Insights

The research team selected clinical isolates from a patient in whom P. aeruginosa developed resistance to ceftolozane-tazobactam during therapy. Whole genome sequencing revealed that both ampC (C548A, G183D) and ampD (C469T, H157Y) mutations coincided with this resistance phenotype. To isolate their respective effects, the authors engineered these mutations into the PAO1 reference strain and produced single and double mutants. Parallel reversal mutants were also generated in the resistant clinical background.

Sequential time-kill curve experiments were conducted for all strains, exposing them to varying concentrations of ceftolozane-tazobactam and imipenem. Bacterial counts over time were modeled using a semi-mechanistic PK/PD framework integrating both initial susceptibility (via EC₅₀ values) and adaptive resistance parameters. This approach enabled the researchers to parse out the temporal evolution of resistance and to quantify the impact of each genetic alteration.

Protocol Parameters

• Strain engineering: Homologous recombination was used to introduce ampC (G183D) and ampD (H157Y) mutations into PAO1 and the clinical resistant background.
• Time-kill assays: Sequential time-kill experiments were performed with ceftolozane-tazobactam and imipenem at clinically relevant concentrations, sampling bacterial counts at multiple intervals.
• PK/PD modeling: Semi-mechanistic models incorporated both initial EC₅₀ (drug concentration yielding half-maximal effect) and adaptive resistance emergence rates, enabling separation of inherent and time-dependent resistance components.
• In vitro susceptibility testing: MIC and EC₅₀ values were determined according to standardized protocols, facilitating reproducible measurement of mutation impacts on drug efficacy.

Core Findings and Why They Matter

The study revealed several critical insights:

• The introduction of ampC (G183D) and ampD (H157Y) mutations—alone or in combination—led to substantial, stepwise increases in ceftolozane-tazobactam EC₅₀ values. Notably, the double mutant demonstrated a 29-fold initial increase in EC₅₀ relative to wild-type, rising to 320-fold after adaptive resistance developed (Deroche et al., 2023).
• Adaptive resistance was a major contributor to the observed phenotypes: time-dependent increases in EC₅₀ were significant, highlighting the dynamic nature of resistance beyond static MIC assays.
• Reversal of both mutations in the resistant clinical isolate led to a dramatic reduction in EC₅₀ (from 80.5 mg/L to 6.77 mg/L), confirming the causative role of these mutations.
• Interestingly, the ampC (G183D) mutation, while conferring resistance to ceftolozane-tazobactam, restored susceptibility to imipenem and prevented adaptive resistance to the latter, suggesting a trade-off in β-lactamase substrate specificity.

These results underscore the complexity of resistance emergence in P. aeruginosa and the limitations of standard MIC-based surveillance. Semi-mechanistic PK/PD modeling provides a richer, time-resolved understanding of how specific mutations modulate both initial and adaptive resistance patterns, informing antibiotic stewardship and drug development strategies.

Comparison with Existing Internal Articles

Several recent technical resources have emphasized the utility of ceftolozane sulfate for translational resistance research. For instance, the article "Ceftolozane Sulfate: Optimizing Antibacterial Assays & PK/PD Models" highlights advances in in vitro and in vivo modeling of resistant P. aeruginosa, including protocol enhancements and troubleshooting for antibacterial susceptibility workflows. Similarly, "Ceftolozane Sulfate: Optimized Workflows for Antibacterial Research" details robust assay designs leveraging high-purity ceftolozane sulfate for reproducible PK/PD and resistance studies. The present reference study complements these resources by providing quantitative, mutation-specific insights and validating the importance of dynamic resistance modeling beyond traditional MIC endpoints. Together, these publications support a holistic, protocol-driven approach to resistance surveillance and PK/PD research with ceftolozane sulfate.

Limitations and Transferability

While the study offers a robust framework for dissecting mutation-driven resistance, several limitations warrant consideration. The experimental system, based on engineered mutations in PAO1 and isogenic clinical backgrounds, does not capture the full spectrum of genetic and phenotypic diversity present in clinical P. aeruginosa populations. The semi-mechanistic PK/PD model, although powerful, is parameterized on specific strain-drug combinations and may require adaptation for other resistance mechanisms or antibiotic classes. Finally, the time-kill and PK/PD modeling approaches, although superior to static MIC measurements, are more resource-intensive and may not be feasible for routine clinical microbiology labs. Nonetheless, the methodology is transferable to other research settings aiming to elucidate complex resistance mechanisms and optimize antibacterial therapy.

Research Support Resources

To facilitate similar experimental workflows, researchers can utilize Ceftolozane sulfate (SKU C8753), a high-purity, time-dependent oxyimino cephalosporin suitable for in vitro antibacterial susceptibility assays, neutropenic mouse thigh infection models, and PK/PD studies. Its robust stability and well-characterized activity spectrum against P. aeruginosa—including chromosomal AmpC β-lactamase-expressing strains—make it a reliable reagent for resistance mechanism elucidation and translational research. For detailed protocols and troubleshooting strategies, see additional guidance in recent workflow-focused articles (e.g., Advanced Protocols for Antibacterial Assays). APExBIO provides further support for researchers seeking to replicate or extend PK/PD modeling studies with ceftolozane sulfate.